Selumetinib in Children with Inoperable Plexiform Neurofibromas.

BACKGROUND— No approved therapies exist for inoperable plexiform neurofibromas in patients with neurofibromatosis type 1. METHODS— We conducted an open-label, phase 2 trial of selumetinib to determine the objective response rate among patients with plexiform neurofibromas and to assess clinical benefit. Children with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas received oral selumetinib twice daily at a dose of 25 mg per square meter of body-surface area on a continuous dosing schedule (28-day cycles). Volumetric magnetic resonance imaging and clinical outcome assessments (pain, quality of life, disfigurement, and function) were performed at least every four cycles. Children rated tumor pain intensity on a scale from 0 (no pain) to 10 (worst pain imaginable).

[1]  T. Rosenbaum,et al.  Trametinib Induces Neurofibroma Shrinkage and Enables Surgery , 2019, Neuropediatrics.

[2]  S. Steinberg,et al.  Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1 , 2018, Neuro-oncology.

[3]  B. Korf,et al.  NFM-06. NF106: PHASE 2 TRIAL OF THE MEK INHIBITOR PD-0325901 IN ADOLESCENTS AND ADULTS WITH NF1-RELATED PLEXIFORM NEUROFIBROMAS: AN NF CLINICAL TRIALS CONSORTIUM STUDY , 2018, Neuro-Oncology.

[4]  C. Pratilas,et al.  Trametinib in pediatric patients with neurofibromatosis type 1 (NF-1)–associated plexiform neurofibroma: A phase I/IIa study. , 2018 .

[5]  M. Prados,et al.  A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study , 2017, Neuro-oncology.

[6]  N. Ratner,et al.  Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas. , 2016, The New England journal of medicine.

[7]  S. Steinberg,et al.  Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas , 2016, Neuro-oncology.

[8]  K. Flaherty,et al.  Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer. , 2016, JAMA ophthalmology.

[9]  C. Marcus,et al.  Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1 , 2016, Neurology.

[10]  R. Avery,et al.  Separation of outer retinal layers secondary to selumetinib. , 2016, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[11]  H. Elhalawani,et al.  Risk of Selected Cardiovascular Toxicities in Patients With Cancer Treated With MEK Inhibitors: A Comparative Systematic Review and Meta-Analysis , 2015, Journal of global oncology.

[12]  M. Kanstrup,et al.  Evaluating the Statistical Properties of the Pain Interference Index in Children and Adolescents with Chronic Pain , 2015, Journal of developmental and behavioral pediatrics : JDBP.

[13]  J. Aviña-Zubieta,et al.  Approaches for estimating minimal clinically important differences in systemic lupus erythematosus , 2015, Arthritis Research & Therapy.

[14]  Alan Cantor,et al.  Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. , 2015, Neuro-oncology.

[15]  P. Hinds,et al.  PROMIS® pediatric self-report scales distinguish subgroups of children within and across six common pediatric chronic health conditions , 2015, Quality of Life Research.

[16]  B. Widemann,et al.  Development and validation of the English Pain Interference Index and Pain Interference Index-Parent report. , 2015, Pain medicine.

[17]  S. Steinberg,et al.  Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas , 2014, Pediatric blood & cancer.

[18]  S. Steinberg,et al.  Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. , 2014, Neuro-oncology.

[19]  B. Korf,et al.  Recommendations for imaging tumor response in neurofibromatosis clinical trials , 2013, Neurology.

[20]  B. Korf,et al.  Optimizing biologically targeted clinical trials for neurofibromatosis , 2013, Expert opinion on investigational drugs.

[21]  G. Page,et al.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors. , 2013, The Journal of clinical investigation.

[22]  Alexis Wright,et al.  Clinimetrics corner: a closer look at the minimal clinically important difference (MCID) , 2012, The Journal of manual & manipulative therapy.

[23]  D. Gutmann,et al.  Visual acuity in children with low grade gliomas of the visual pathway: implications for patient care and clinical research , 2012, Journal of Neuro-Oncology.

[24]  L. Kluwe,et al.  Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits. , 2011, The Journal of pediatrics.

[25]  J. Lai,et al.  Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: built using item response theory. , 2011, Journal of clinical epidemiology.

[26]  Michael A Babcock,et al.  Neurofibromatosis Type 1 Revisited , 2009, Pediatrics.

[27]  Jan M Friedman,et al.  Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. , 2008, Neuro-oncology.

[28]  S. Steinberg,et al.  NF1 plexiform neurofibroma growth rate by volumetric MRI , 2007, Neurology.

[29]  J. Varni,et al.  The PedsQL™ as a pediatric patient-reported outcome: reliability and validity of the PedsQL™ Measurement Model in 25,000 children , 2005, Expert review of pharmacoeconomics & outcomes research.

[30]  Walter Grassi,et al.  Minimal clinically important changes in chronic musculoskeletal pain intensity measured on a numerical rating scale , 2004, European journal of pain.

[31]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[32]  Michael Seid,et al.  PedsQL™ 4.0: Reliability and Validity of the Pediatric Quality of Life Inventory™ Version 4.0 Generic Core Scales in Healthy and Patient Populations , 2001, Medical care.

[33]  Jesse A. Berlin,et al.  Defining the clinically important difference in pain outcome measures , 2000, PAIN.

[34]  W. Downie,et al.  Studies with pain rating scales. , 1978, Annals of the rheumatic diseases.

[35]  B. R. Korf,et al.  Plexiform neurofibromas. , 1999, American journal of medical genetics.

[36]  R. Cawthon,et al.  The neurofibromatosis type 1 gene. , 1993, Annual review of neuroscience.